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Abstract
Background: In the Czech Republic, two-dose immunization against mumps achieves 98 % coverage. The routine
reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated
individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on
mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization.
Methods: We analysed data on incident mumps cases reported to the Czech national surveillance system in
2007–2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region,
the association between vaccination and the most frequent mumps complications and hospitalization was evaluated.
The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated
groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa)×100. We estimated the risk of mumps
complications by the time from vaccination.
Results: From total of 9663 mumps analysed cases 5600 (58 %) occurred in males. The mean age at the
disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while
1.6 % developed meningitis, 0.2 % encephalitis, and 0.6 % pancreatitis. Mumps orchitis occurred in 659 (11.8 %) male
cases. In total, 1192 (12.3 %) patients required hospitalization. Two doses of vaccine received by 81.8 % cases
significantly reduced the risk of hospitalization: ORa 0.29 (95 % CI: 0.24, 0.35). Two doses showed statistically
significant VEa 64 % (95 % CI: 46, 79) for meningitis, 93 % (95 % CI: 66, 98) for encephalitis in all cases, and
72 % (95 % CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74 % and
56 % in the most affected age groups 10–14, 15–19, and 20–24 years, respectively. Among 7850 two-dose
recipients, the rate of complications rose from below 1 to 16 % in categories up to 6 years and 24 and more
years after the second dose, respectively.
Conclusions: This study demonstrates a significant preventive effect of two-dose vaccination against mumps
complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases
with time interval from vaccination. Teenagers and young adults were the most affected age groups.
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Background
Mumps is an acute infection affecting humans and caused
by the mumps virus, an RNA virus of the genus Rubula-
virus, family Paramyxoviridae [1]. A third of mumps
infections arise without recognised symptoms [2]. Clinic-
ally apparent mumps is manifested mainly by the swelling
and inflammation of one or both parotid glands. Approxi-
mately ten percent of mumps cases develop complications.
Epididymo-orchitis is the most frequent complication.
Neurological complications as meningitis and less com-
mon encephalitis arise, seldom resulting in permanent
unilateral deafness. Pancreatitis occurs rather commonly.
Oophoritis or mastitis in females is diagnosed less fre-
quently. Other complications as arthritis, myocarditis,
nephritis, and polyneuropathy are infrequent. The case
fatality rate is very low, with death reported in 1.5 % of
mumps cases associated with encephalitis [2].
Complications of mumps worsen and prolong the
course of disease, often require hospitalization and thus
increase the economic and overall burden of the disease.
Mumps is transmitted by direct contact, droplet
spread, or contaminated fomites. The incubation period
averages about 16–18 days (range 12–25 days) [1–4].
The spread of the mumps virus can cause mumps out-
breaks in susceptible populations. An epidemic of
mumps was described by Hippocrates as early as in the
5th century BC [4, 5]. Resurgence and outbreaks of
mumps have been reported in many European countries
in recent years [6–15].
One mumps virus serotype [3] and based on the phylo-
genetic analysis, 12 genotypes of the mumps virus were
identified (designated A-N, with E and M being un-
assigned) [16]. Mumps is preventable by immunization.
Vaccines containing live attenuated mumps virus have
been used worldwide, usually as part of the combined
measles, mumps, and rubella vaccines known as MMR.
Mumps is a common childhood infection in unimmu-
nized individuals, but in highly vaccinated popula-
tions, the disease affects mainly adolescents and
young adults [7, 8, 10, 15].
In the Czech Republic, the universal compulsory vac-
cination against mumps was introduced in 1987, with
the measles and mumps vaccine MOPAVAC® and mono-
valent vaccine PAVIVAC®. The trivalent MMR vaccine
TRIVIVAC® was administered since 1995. All previously
named vaccines contained the Jeryl-Lynn vaccine strain.
Since 2008, the MMR vaccine PRIORIX® comprising
the RIT 4385 strain has been used in the vaccination
calendar. In addition, on an optional basis, parents
may purchase the PRIORIX TETRA® vaccine (against
MMR and varicella) for their child, available on the
market since 2007.
The national immunization schedule comprises two
doses, the first one given from the 15th month of age
and the second one given 6–10 months or more after
the first dose [17–20]. The vaccination coverage has
been evaluated annually by administrative surveys and
in the period 2007–2012 ranged from 97.76 to
98.51 % for two doses and from 1.64 to 0.92 % for
one dose only [21].
The Czech national surveillance of mumps is compre-
hensive, countrywide with compulsory reporting. The
EU case definition was enshrined in the legislation in the
end of 2008. Hospital physicians and general practi-
tioners report all clinical mumps cases to the regional
public health authority. Regional epidemiologists bring
together the patient's personal, demographic, clinical,
laboratory, and epidemiological data, including the vac-
cination status. Data on each mumps case are entered
with the International Classification of Diseases, Tenth
revision (ICD10) code into the national electronic
reporting system called EPIDAT. Case based data are
transferred weekly from the regional to the national level
where they are further analysed and outcomes are pub-
lished monthly [22, 23]. Yearly anonymous case based
data are reported to the European Surveillance System
(TESSy) database operated by the European Centre for
Disease Prevention and Control (ECDC). In the Czech
Republic, the data from the national mandatory notifica-
tion are accessible only for authorised personnel of the
public health service including the National Institute of
Public Health. For purpose of public health policy data
are analysed, results published to inform professionals
and public in order to support prevention of infectious
diseases and health protection.
Before the introduction of the mumps vaccine to the
Czech Republic, mumps epidemics occurred at regular
3–4-year intervals, with tens of thousands of reported
cases and a maximum of over 100,000 mumps patients
in the 1970s [4, 19, 23]. In the post-vaccination period,
mumps incidence sharply declined. However, occasional
regional and national outbreaks with several thousand
cases occurred in 1995-96, 2005–2006, and 2011–2012
[17–19, 23–25]. Recent two large outbreaks were caused
by genotype G mumps virus [18, 26]. In the latest years,
mumps affects mainly adolescents, young adults, and
school age children and various complications such as
orchitis, meningitis, and pancreatitis arise quite fre-
quently not only in unvaccinated but also in immunized
individuals.
Despite the comprehensive surveillance and mandatory
vaccination strategy with high vaccination coverage being
in place in the Czech Republic, mumps cases and mumps
complications continue to occur.
Various studies of vaccine effectiveness against mumps
complications were conducted in some countries [7, 27, 28];
nevertheless, no relevant analysis to inquire more deeply
the situation in the Czech Republic is available.
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Objective
The aim of the study was to assess the effect of vaccin-
ation on mumps complications and hospitalization need
in mumps cases reported to the Czech national surveil-
lance system during the period 2007–2012. Furthermore,
the influence of the time interval from the second dose
of vaccine to the development of complications was
considered. The present study was conducted in order





Data were derived from the electronic Czech national
surveillance system EPIDAT.
Case definition
A case was defined as any patient with clinical mumps
reported to the EPIDAT under the ICD10 code “B26”
with onset of the disease in the six-year period between
2007–2012.
Inclusion criteria
All patients with clinical mumps whose clear data on
age, sex, date and place of disease onset, type of com-
plications of the disease, if any, hospitalization, and
vaccination history were available in their records.
Records with unclear items were clarified with the re-
spective epidemiologist of the relevant regional public
health authority.
Exclusion criteria
All cases with missing, ambiguous, or unclear data on vac-




All subjects analysed in this study had mumps. The epi-
demiological characteristics of the patients with mumps,
i.e. age, gender, year of onset, complications, hospitalisa-
tion, and vaccination status, were analysed descriptively
using absolute and relative frequencies.
To assess the effect of vaccination we compared
mumps complications and hospitalization in vaccinated
and unvaccinated mumps cases. No controls were sam-
pled from population, no uninfected comparison group
was in the study, only mumps cases reported to the
surveillance were analysed.
Univariate and multiple logistic regression models
were employed to assess the association between vaccin-
ation status of the analysed mumps cases and the most
frequent mumps complications or hospitalization. The
unadjusted odds ratios (OR) and adjusted odds ratios
(ORa) were calculated. The latter were adjusted for age,
sex, year of onset, and the third level of administrative
region. According to the Nomenclature of Units for
Territorial Statistics there are 14 administrative regions
of the third level in the Czech Republic (NUTS3).
The adjusted vaccine effectiveness (VEa) was com-
puted using the formula VEa = (1-ORa)×100. Vaccine
effectiveness against complications and hospitalization is
perceived as the proportion of mumps cases who might
be protected from complications/hospitalization if previ-
ously vaccinated. The adjusted point estimates in rela-
tion to the effect of vaccination on complications and
hospitalization among unvaccinated and partially and
fully vaccinated mumps cases were compared. Vaccine
effectiveness for the prevention of orchitis was evaluated
in the male population stratified by age groups. The
point estimates for OR, ORa, VEa were supplied with
95 % confidence intervals (95 % CI); results with p < 0.05
were considered statistically significant.
To consider the possible influence of epidemic period
on risk of complications we compared complications
occurrence in two periods: the "non-epidemic 2008–
2009" with predominantly sporadic cases, and the
"epidemic 2011–2012" when the outbreaks occurred.
The logistic regression model was used adjusted for
number of doses.
Furthermore, in order to estimate the influence of the
length of the time interval from the second dose of vac-
cine to the mumps complications, only the data on
mumps cases in two-dose vaccine recipients were ana-
lysed. The mumps cases in two-dose vaccine recipients
were divided into categories by two-year intervals from
the second dose. Additionally, using the multiply logistic
regression model, the relationship between the risk of
any complication and two potential predictors, the time
interval from the second dose and the age at second
dose, was assessed. For this purpose, the first three inter-
vals of 0–1.9, 2–3.9, 4–5.9 years from the second dose
were combined together and served as the reference
time interval category. The odds of complication in each
other category was compared to the reference category
and characterised by odds ratio.
Finally, the locally weighted scatterplot smoothing
(LOWESS) was used to plot a smooth curve characteriz-
ing the relationship between probability of complications
and time from the second dose.
The statistical analysis was performed in Stata, release
9.2 (StataCorp LP, College Station, TX, USA).
Results
Description of the analysed mumps cases
The mumps cases were unevenly distributed within the
six-year period; the incidence of the notified mumps
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cases per 100.000 population was 12.6; 3.9; 3.4; 10.2;
27.5; 37.1 in the respective six years 2007–2012. The
highest morbidity was reported during the outbreaks in
2011–2012.
Out of 9898 mumps cases reported in the six-year
study period, 9663 met the inclusion criteria and were
included in the analysis. The rate of exclusion was 2.6 %.
The description of the 9663 cases analysed is pro-
vided in Table 1. Of these cases, 5600 (58 %) were
males. The mean age at disease onset was 17.3, me-
dian 16 years (range 0–90). The age group 15–19 was
the most affected.
Seventeen percent of mumps cases occurred in unvac-
cinated individuals, 71 (0.7 %) cases in single-dose vac-
cine recipients, 7907 (81.8 %) cases in two-dose vaccine
recipients, and 23 (0.2 %) cases in three-dose vaccine
recipients.
Ninety percent of cases had no clinical complications.
The most frequent complication was orchitis, reported
in 659 (11.8 %) male patients. Meningitis affected 155
(1.6 %), pancreatitis 62 (0.6 %), and encephalitis 15
(0.2 %) of the study patients. A total of 1192 (12.3 %)
mumps cases required hospitalization.
Association between vaccination and hospitalization or
clinical complications of mumps
After one dose of the mumps strain containing vaccine,
a statistically significant (p < 0.05) protective effect
against any complication ORa 0.32 (95 % CI: 0.11, 0.91)
and for hospitalization was detected ORa 0.32 (95 % CI:
0.13, 0.76) (Table 2).
In two-dose vaccine recipients, the risk was signifi-
cantly (p < 0.001) reduced (in comparison to unvaccin-
ated) for hospitalization in all patients ORa 0.29 (95 %
CI 0.24, 0.35) and in males 0.26 (95 % CI: 0.21, 0.33),
reflecting VEa of 71 % (95 % CI: 65, 76) and 74 % (95 %
CI: 67, 79), respectively (Table 2).
In two-dose vaccine recipients, the following signifi-
cant (p < 0.001) protective effects VEa were observed:
68 % (95 % CI: 61, 75) for any complication, 64 % (95 %
CI: 46, 79) for meningitis, 93 % (95 % CI: 66, 98) for en-
cephalitis in all patients, and 72 % (95 % CI: 64, 78) for
orchitis in males. The computed ORa of 1.18 (95 % CI:
0.49, 2.86) for pancreatitis was the only non-significant
result (p = 0.706), (Table 2).
Orchitis was the most common among adolescents
and young males between 15–34 years (Table 3). The
proportions of patients with orchitis were the highest
in the age groups 25–34 (38.2 %), 35–44 (26.5 %),
and 20–24 (18.7 %). Two-dose vaccine effectiveness
against orchitis stratified by age groups significantly
declined from VEa 81 % (95 % CI: 13, 96) and 74 %
(95 % CI: 45, 88) to 56 % (95 % CI: 34, 71) in the
age groups 10–14, 15–19, 20–24 years, respectively,
and then slightly rose again to VEa 60 % (95 % CI:
27, 78) in the 25–34-year-olds. In small boys and
older men, mumps orchitis was reported sporadically
(Table 3).
Table 4 shows comparison of the risk of complications
in epidemic and non-epidemic periods. There was no
significant difference between these two periods in oc-
currence of all complications, orchitis, meningitis and
encephalitis. Significantly lower risk in epidemic years
was for pancreatitis ORa 0.23 (95 % CI: 0.12, 0.46) and
for hospitalization ORa 0.66 (95 % CI: 0.53, 0.81).
Influence of the time interval from the second dose of
vaccine on mumps complications
In total, 7850 mumps cases had a record with clearly
documented two-dose immunization. We divided these
cases into 12 categories by two-year intervals from the
second dose of vaccine and the thirteenth category was
24 years or more from the second dose of vaccine. Only
a few cases with complications occurred till six years
from the second dose, with a proportion below 1 %.
Then the percentage of complications increased to
16.3 % in those vaccinated 24 or more years before the
disease onset. The highest numbers of complications
occurred in patients immunized approximately 12–20
years before disease onset (Table 5). The mean time
interval between the second dose and the disease onset
was 12.8 years (standard deviation 4.8). The mean age at
the second dose was 2.2 years (standard deviation 0.8)
with range from 20 months to 16 years. Age at the
second dose turned out to be an independent predictor
of complications. In the individuals who received the
second dose after four years of age, the odds of compli-
cations were significantly (p < 0.001) higher.
Figure 1 shows the relationship between time interval
from the second dose to disease onset and the age at the
second dose with regards to the occurrence of complica-
tions. Majority of cases were vaccinated to 3 years of
age. Only 291 patients received the second dose later.
Those who were vaccinated later tended to contract the
disease earlier after the completion of the vaccination
compared to those vaccinated properly according to the
recommended schedule.
Figure 2 shows how the probability of complications
increases with time interval from the second dose (as a
continuous variable).
Discussion
This study was the first investigation of the vaccine ef-
fectiveness against clinical complications of mumps and
need for hospitalization in the Czech Republic, based on
the national surveillance data.
A statistically significant effectiveness of the mumps
vaccination on the prevention of orchitis, meningitis,
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encephalitis, and hospitalization was documented in
this study. The most frequent clinical complication
was orchitis. The most afflicted age groups were teen-
agers, adolescents, and young adults, similarly to
some other studies [7, 10]. The findings of the risk of
orchitis growing with age of male corresponds with
the reference, in which the older age at infection is
associated with a higher risk of certain complications,
particularly orchitis [2].
The point estimates in this study are slightly different
from the results reported by Dutch and British authors
[7, 27]. Anyway, all three studies have proven the pro-
tective effect of mumps vaccination with two doses. In
two-dose vaccine recipients the risk was reduced for
orchitis (ORa 0.64, 0.26, 0.28) and for hospitalization
(ORa 0.45, 0.18, 0.29) in England and Wales, the
Netherlands, and the Czech Republic, respectively.
In addition, a significant protective effect against clin-
ical complications and hospitalization was observed
among single-dose vaccine recipients in this study. The
national immunization calendar prescribes two MMR
doses. The second dose of MMR vaccine is not a
booster, but rather is given as another individual dose. In
this study, there were small numbers of mumps cases
and complications among the single-dose recipients.
Even higher protective effect against all complications
has been reported in the Netherlands [7] in single-dose
and two-dose vaccine recipients, with ORa of 0.29 (95 %
CI: 0.14, 0.62) and 0.24 (95 % CI: 0.14, 0.39), respect-
ively. Therefore, the general importance of mumps
vaccination should be emphasized. Each single dose of
mumps vaccine can contribute to the protection against
mumps complications.
To see if the outbreak period can somehow affect the
occurrence of particular complications we compared
epidemic and non-epidemic years. No substantial differ-
ences were seen in the occurrence of severe complica-
tions with exception of pancreatitis. The odds of
hospitalization was lower during the epidemic period,
this might be due to the limited capacities in the hospital
health care settings.
Another important outcome of this investigation was
the growing risk and thus decreasing protection against
mumps complications with time from the second vac-
cine dose as prescribed in the national immunization
Table 1 Characteristics of mumps cases, Czech Republic,
2007–2012





























75 + 4 0.0
Vaccination status
0 doses 1662 17.2
1 dose 71 0.7
2 doses 7907 81.8
















Note: aonly males, of 5600 males
Orlíková et al. BMC Public Health  (2016) 16:293 Page 5 of 10
schedule. Nevertheless, the risk still remained lower in
comparison with the unvaccinated. Several patients who
received the dose during the incubation period, mostly
within the immunization campaign in response to the
2011 mumps outbreak in the Ústí nad Labem Region
[24], developed mumps a few days later.
The patients immunized later than at four years of age
had higher odds of complications. Unfortunately, routine
surveillance data do not allow a clear interpretation of this
finding. Various factors, e.g. an underlying or chronic
disease, may have played a role in delayed vaccination [29].
When comparing the results of this study with those
of the sero-epidemiological survey conducted in the
population of the Czech Republic in 2013 [30], a similar
downward trend in the specific antibody protection
against mumps was revealed by the serosurvey in teen-
agers from the highly vaccinated general population.
Thus the results of this study might indirectly support
the probable impact of the waning immunity on increase
in mumps cases and complications with time from the
second vaccine dose in the vaccinated population. The
issues of the waning immunity or secondary vaccine
failure [31] and growing risk of developing mumps with
increasing time after vaccination have been addressed
[32, 33]. Due to the secondary vaccine failure after the
previous vaccination the decreased or insufficient spe-
cific antibody level is unable to protect an individual
infected by circulating wild strain of virus from disease
development. Nevertheless, in the present study no
laboratory data were analysed and the immunity status
thus assumption of waning immunity couldn’t be valid-
ate directly. No uninfected comparison group was in the
study. We also have to admit that orchitis as the most
frequent complications contributed essentially to the
number and proportion of all complications. Majority of
the orchitis cases were among adolescents and young
adults, and in the older age the risk of orchitis is
higher [2]. It should be mentionded as a theoretical
possibility of an intrinsic bias. Additionally, it was not
possible to differentiate between primary and second-
ary vaccine failure in particular vaccinated cases in-
cluded in this study.
Table 2 Association between vaccination and mumps complications or hospitalization, vaccine effectiveness, Czech Republic,
2007–2012





number of cases (%)
Unadjusted odds
ratio (95 % CI)
Adjustedc odds
ratio (95 % CI)
P value Adjustedc vaccine
effectiveness % (95 % CI)
Any complication 0 1662 430 (25.9) Ref Ref
1 71 4 (5.6) 0.17 (0.06, 0.47) 0.32 (0.11, 0.91) 0.033 68 (9, 89)
2 7907 516 (6.5) 0.20 (0.17, 0.23) 0.32 (0.25, 0.39) <0.001 68 (61, 75)
Orchitisa 0 1006 322 (32.0) Ref Ref
1 33 3 (9.1) 0.21 (0.06, 0.70) 0.34 (0.10, 1.16) 0.086 66 (-16, 10)
2 4548 333 (7.3) 0.17 (0.14, 0.20) 0.28 (0.22, 0.36) <0.001 72 (64, 78)
Meningitis 0 1662 66 (4.0) Ref Ref
1 71 1 (1.4) 0.35 (0.05, 2.52) 0.50 (0.07, 3.80) 0.502 50 (-280, 93)
2 7907 87 (1.1) 0.27 (0.19, 0.37) 0.34 (0.21, 0.54) <0.001 64 (46, 79)
Encephalitis 0 1662 12 (0.7) Ref Ref
1 71 0 (0.0)
2 7907 3 (0.0) 0.05 (0.01, 0.19) 0.07 (0.02, 0.34) 0.001 93 (66, 98)
Pancreatitis 0 1662 15 (0.9) Ref Ref
1 71 0 (0.0)
2 7907 47 (0.6) 0.66 (0.37, 1.18) 1.18 (0.49, 2.86) 0.706 -18 (-186, 51)
Hospitalization 0 1662 511 (30.7) Ref Ref
(males + females) 1 71 6 (8.5) 0.21 (0.09, 0.48) 0.32 (0.13, 0.76) 0.010 68 (24, 87)
2 7907 673 (8.5) 0.21 (0.18, 0.24) 0.29 (0.24, 0.35) <0.001 71 (65, 76)
Hospitalization 0 1006 417 (41.5) Ref Ref
(males onlya) 1 33 4 (12.1) 0.19 (0.07, 0.56) 0.30 (0.10, 0.89) 0.030 41 (11, 90)
2 4548 502 (11.0) 0.18 (0.15, 0.20) 0.26 (0.21, 0.33) <0.001 74 (67, 79)
Note
Ref - reference category (unvaccinated)
aonly males, of 5587 males
b23 cases (13 in males and 10 in females) in three-dose vaccine recipients were not included in the analysis
cadjusted for age, gender, year of onset, and region (NUTS3)
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This study does not investigate the impact of particu-
lar vaccine types on mumps complications. Vaccine
effectiveness is not compared between different vaccine
virus strains. Generally, both vaccine strains used in the
Czech Republic (Jeryl Lynn and RIT 4385) are derived
from genotype A [19]. Both vaccine strains are consid-
ered to be effective against the live mumps virus of
genotype G, identified in some outbreak cases in 2006
and 2012 [26].
The authors are aware of the study limitations. Where
appropriate, correction was applied for possible biases in
particular steps of the present research protocol. To
minimize the selection bias the data were collected
directly from the national database. In the analyses, the
multiple logistic regression adjusting for the important
predictors (age, gender, year of onset, NUTS3 regions)
was used to correct for possible information biases. The
fact that the data originate from the routine surveillance
system was taken into account. In the process of data
collection and data cleaning, great efforts were made to
clarify unclear, ambiguous, or missing data to minimize
loss of records. Despite the notification is comprehensive,
mandatory, enshrined in law [34, 35], and stable within
the recent decades, the passive surveillance system might
be subject to underreporting.
Another limitation might be that all reported
mumps cases were included in this study regardless
of their classification. The majority of cases were
laboratory confirmed or epidemiologically linked to a
confirmed case. Suspected cases are reported rarely
based on typical clinical symptoms. Therefore, the no-
tified mumps cases are unlikely to have been subject
to misdiagnosis. The study relies on careful appraisal
of each notified mumps case by the reporting phys-
ician and epidemiologist who performed epidemio-
logical investigation of all reported cases.
Table 3 Association between vaccination and orchitis in males, by age group, Czech Republic, 2007–2012




(% of age group)
of cases in males
ORCHITIS - number
(%) of cases by
number of doses
Odds ratiob (95 % CI) Vaccine effectivenessb
% (95 % CI)
0 doses 1 dose 2 doses 1 dose 2 doses 1 dose 2 doses
0 9 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
1–4 140 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
5–9 670 4 (0.6 %) 0 (0.0 %) 0 (0.0 %) 4 (100.0 %)
10–14 1161 30 (2.6 %) 2 (6.7 %) 0 (0.0 %) 28 (93.3 %) 0.19 (0.04, 0.87) 81 (13, 96)
15–19 2088 219 (10.5 %) 10 (4.6 %) 1 (0.5 %) 208 (95.0 %) 0.38 (0.04, 3.61) 0.26 (0.12, 0.55) 62 (-261, 96) 74 (45, 88)
20–24 690 129 (18.7 %) 50 (38.8 %) 1 (0.8 %) 78 (60.5 %) 0.49 (0.06, 4.28) 0.44 (0.29, 0.66) 51 (-328, 94) 56 (34, 71)
25–34 608 232 (38.2 %) 216 (93.1 %) 1 (0.4 %) 15 (6.5 %) 0.49 (0.05, 4.75) 0.40 (0.22, 0.73) 51 (-375, 95) 60 (27, 78)
35–44 117 31 (26.5 %) 31 (100.0 %) 0 (0.0 %) 0 (0.0 %)
45–54 68 11 (16.2 %) 11 (100.0 %) 0 (0.0 %) 0 (0.0 %)
55–64 30 1 (3.3 %) 1 (100.0 %) 0 (0.0 %) 0 (0.0 %)
65+ 6 1 (16.7 %) 1 (100.0 %) 0 (0.0 %) 0 (0.0 %)
Total 5587 658 (11.8 %) 322 (48.9 %) 3 (0.5 %) 333 (50.6 %) 0.21 (0.06, 0.70) 0.17 (0.14, 0.20) 79 (30, 94) 83 (80, 86)
Note
a13 male three-dose vaccine recipients were not included in this analysis
breference category is 0 doses
Table 4 Risk of complications in epidemic years 2011–2012 in comparison to non-epidemic years 2008–2009
Adjusteda odds ratio p value 95 % confidence interval
Any complication 0.90 0.415 0.70, 1.15
Orchitis 1.02 0.896 0.75, 1.37
Meningitis 1.32 0.390 0.70, 2.47
Encephalitis 2.12 0.470 0.27, 16.34
Meningitis + encephalitis 1.39 0.287 0.76, 2.53
Pancreatitis 0.23 <0.001 0.12, 0.46
Hospitalization (male + female) 0.66 <0.001 0.53, 0.81
Hospitalization (male only) 0.70 0.005 0.54, 0.89
Note
aodds ratio adjusted for number of doses
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This research might contribute to a better understanding
of why mumps and mumps outbreaks occur in the Czech
population with a high vaccination coverage. Recently, the
Czech population has not been notably exposed to the nat-
ural booster by the wild virus. Supposing some gaps in the
protection, herd immunity might drop to a certain thresh-
old and then the wider spread of mumps might hit suscep-
tible individuals. In the present investigation, the highest
numbers of mumps cases and complications were in the
age group 15–19 years.
The current Czech two-dose vaccination schedule is
completed in children at the age of 21 to 25 months. The
present results show that mumps and the clinical compli-
cations of mumps are quite rare during approx. 6-year
period after the second dose. The epidemiological situ-
ation where mumps and complications affect predomin-
antly teenagers and young adults evoke thinking about the
need for updating the immunization calendar. The post-
ponement of the second dose to an older age could be
discussed. However, to determine the optimal age and
adjust the schedule will require further investigation,
taking into account laboratory and serological survey
results. The epidemiological situation of measles and
rubella should also be considered when speaking about
Table 5 Complications in vaccinated mumps patients by time from the second dose, Czech Republic, 2007–2012
Time from the second dose MUMPS COMPLICATIONS COMPLICATIONS Adjustedb odds ratio 95 % CI p value
in years number of cases number of cases % of mumps cases
with complications
0–1.9 106 1 0.94 Refa
2–3.9 287 1 0.35
4–5.9 435 4 0.92
6–7.9 650 11 1.69 2.49 0.91, 6.79 0.074
8–9.9 652 10 1.53 2.21 0.79, 6.13 0.126
10–11.9 865 27 3.12 4.70 1.92, 11.47 0.001
12–13.9 1268 79 6.23 10.3 4.33, 23.21 <0.001
14–15.9 1584 128 8.08 13.59 5.93, 31.13 <0.001
16–17.9 1129 136 12.05 21.28 9.29, 48.76 <0.001
18–19.9 447 52 11.63 20.14 8.53, 47.55 <0.001
20–21.9 240 31 12.92 22.97 9.40, 56.11 <0.001
22–23.9 144 21 14.58 26.70 10.51, 67.87 <0.001
24 and later 43 7 16.28 30.41 9.67, 95.59 <0.001
Total 7850 508 6.47
Note
areference category 0–5.9 compounded from three categories: 0–1.9, 2–3.9, 4–5.9 years
bodds ratio adjusted for age at the 2nd dose
Fig. 1 Relationship between time from the second vaccine dose to
mumps onset and age at the second dose, by complications
Fig. 2 Relationship between probability of complications and time
from the second dose
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the combined MMR vaccine routinely used in the Czech
immunization practice.
Conclusions
Results of the present analysis confirm the positive
preventive effect of vaccination on mumps complica-
tions in the context of the epidemiological situation
of mumps, vaccination policy, and surveillance system
in the Czech Republic.
The risk of clinical complications and hospitalization is
lower in the vaccinated than in the unvaccinated patients
with mumps. Immunization with two doses of mumps
strain containing vaccines significantly reduces the risk of
encephalitis, meningitis, orchitis and hospitalization. The
risk of complications is not influenced substantially by the
epidemic period. Orchitis, the most frequent complication
of mumps, affects mainly teen-age, adolescent and young
adult males. Within these age groups the vaccine effective-
ness for orchitis declines with the growing age.
In two-dose recipients the risk of all complications in-
creases and the protection declines with time interval
since the previous vaccination. Additional studies would
be needed to investigate the serological background of
findings in the present study. To decrease the burden of
mumps and mumps complications in the most affected
age groups the adjustment of the vaccination schedule
could be discussed. Further studies are required to deter-
mine the best approach to immunization in compliance
with the current needs.
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